Astaxanthin.

Added Astaxanthin with an Emerging rating, skin and metabolic evidence, null findings, and safety cautions.

Adds a distinct oral carotenoid supplement not previously covered in the library, separating preliminary skin and biomarker findings from unproven disease-prevention and longevity claims.

• Skin-ageing systematic review and meta-analysis (2021)
• Skin-health clinical systematic review (2021)
• Randomized UV-response trial (2018)
• Prediabetes and dyslipidaemia randomized trial (2023)
• Prediabetes and type 2 diabetes meta-analysis (2026)
• EFSA supplement safety assessment (2020)
• EFSA assessment of additional food uses (2025)
• Suspected warfarin interaction case report (2019)